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AbstrACt
Objectives To compare the effectiveness of oral versus 
intramuscular (IM) vitamin B12 (VB12) in patients aged ≥65 
years with VB12 deficiency.
Design Pragmatic, randomised, non- inferiority, 
multicentre trial in 22 primary healthcare centres in 
Madrid (Spain).
Participants 283 patients ≥65 years with VB12 deficiency 
were randomly assigned to oral (n=140) or IM (n=143) 
treatment arm.
Interventions The IM arm received 1 mg VB12 on 
alternate days in weeks 1–2, 1 mg/week in weeks 3–8 
and 1 mg/month in weeks 9–52. The oral arm received 1 
mg/day in weeks 1–8 and 1 mg/week in weeks 9–52.
Main outcomes Serum VB12 concentration normalisation 
(≥211 pg/mL) at 8, 26 and 52 weeks. Non- inferiority would 
be declared if the difference between arms is 10% or less. 
Secondary outcomes included symptoms, adverse events, 
adherence to treatment, quality of life, patient preferences 
and satisfaction.
results The follow- up period (52 weeks) was completed 
by 229 patients (80.9%). At week 8, the percentage of 
patients in each arm who achieved normal B
12 levels 
was well above 90%; the differences in this percentage 
between the oral and IM arm were −0.7% (133 out of 135 
vs 129 out of 130; 95% CI: −3.2 to 1.8; p>0.999) by per- 
protocol (PPT) analysis and 4.8% (133 out of 140 vs 129 
out of 143; 95% CI: −1.3 to 10.9; p=0.124) by intention- 
to- treat (ITT) analysis. At week 52, the percentage of 
patients who achieved normal B
12 levels was 73.6% in the 
oral arm and 80.4% in the IM arm; these differences were 
−6.3% (103 out of 112 vs 115 out of 117; 95% CI: −11.9 
to −0.1; p=0.025) and −6.8% (103 out of 140 vs 115 
out of 143; 95% CI: −16.6 to 2.9; p=0.171), respectively. 
Factors affecting the success rate at week 52 were age, 
OR=0.95 (95% CI: 0.91 to 0.99) and having reached 
VB12 levels ≥281 pg/mL at week 8, OR=8.1 (95% CI: 
2.4 to 27.3). Under a Bayesian framework, non- inferiority 
probabilities (Δ>−10%) at week 52 were 0.036 (PPT) 
and 0.060 (ITT). Quality of life and adverse effects were 
comparable across groups. 83.4% of patients preferred 
the oral route.
Conclusions Oral administration was no less effective 
than IM administration at 8 weeks. Although differences 
were found between administration routes at week 52, 
the probability that the differences were below the non- 
inferiority threshold was very low.
trial registration numbers NCT 01476007; EUDRACT 
(2010-024129-20).
strengths and limitations of this study
 ► This is the largest and longest follow- up randomised 
clinical trial in patients aged ≥65 years with VB12 
deficiency.
 ► In addition to VB12 levels, this study incorporates 
patient- reported outcomes such as symptoms, qual-
ity of life and patient preferences.
 ► The study design did not allow patient blinding; 
however, the main outcome measurement was 
objective.
 ► The rates of loss to follow- up were low at week 8 
and week 26 and higher at week 52, consistent with 
pragmatically designed clinical trials.
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IntrODuCtIOn
Vitamin B12 (VB12) is an essential nutrient for the 
synthesis of cellular DNA. It is generally accepted that 
daily needs in adults range from 1 to 2 µg/day,1 but other 
standards recently recommend 3–4 µg/day.2 The Western 
diet is estimated to contain 7–30 µg/day of cobalamin, of 
which 1–5 µg is absorbed and stored (estimated reserves 
of 2–5 mg); therefore, symptoms resulting from a VB12 
deficit would not appear until 3–5 years after establishing 
a low- ingestion or poor- absorption regimen.1 VB12 defi-
ciency can lead to haematological and neuropsychiatric 
disorders,3 as well as cardiovascular risk factors.4 The 
prevalence of VB12 deficiency in the elderly is highly vari-
able across studies, which report values of 1.5%–15%.5–8
In primary care, the most commonly observed causes of 
VB12 deficiency are related to abnormalities in digestion 
(atrophic gastritis, achlorhydria) or absorption (autoim-
mune pernicious anaemia, chronic pancreatitis, Crohn’s 
disease, the effect of medications that alter the mucosa 
of the ileum such as metformin, antacids -proton- pump 
inhibitors and H2- receptor antagonists, antibiotics and 
colchicine)9 or the consequences of surgical resection.10 
A deficiency stemming solely from dietary habits is rare 
and usually affects strict vegans.11 In the elderly, different 
alterations in the processes involved in VB12 absorption 
increase the prevalence of this deficit, which can appear 
in the absence of specific symptoms, thereby hindering 
its diagnosis.12
The traditional treatment for VB12 deficiency consists 
of intramuscular (IM) injection of cyanocobalamin, 
generally 1 mg/day for 1 week, followed by 1 mg/week 
for 1 month and then 1 mg every 1 or 2 months ad perpe-
tuum.10 13 14 The vitamin may, however, be administered 
orally. Several studies have shown serum VB12 concentra-
tions to normalise after taking large oral doses.15 16 Studies 
taking into consideration the patients’ preferences have 
found differences in favour of the oral route.17 18 Further-
more, oral treatment could avoid injection nuisances, 
reduce unnecessary travel for the patients or nurses and 
minimise treatment costs.19
Some authors have questioned the use of oral admin-
istration while others favour it, although no firm conclu-
sions can be drawn due to the methodological limitations 
of the evidence the authors provide.10 20–22 The 2018 
Cochrane Review5 includes three randomised clinical 
trials comparing the effectiveness of oral and IM admin-
istration. There are differences among the trials in terms 
of treatment regimens and follow- up duration, ranging 
from 3 to 4 months, and average age of the patients, as 
well as the frequency and VB12 daily dose for both routes. 
In terms of outcomes, adverse events and cost, the overall 
quality of the evidence was low due to the small number 
of studies and limited sample sizes.23–25 In their conclu-
sions, the authors state the need for trials with improved 
methods for random allocation and masking, larger 
sample sizes and information on other relevant outcome 
variables that are preferably conducted in the primary 
care setting.
The aim of this study was to compare the effectiveness 
of oral- administered and IM- administered VB12 in the 
normalisation of serum VB12 concentrations at 8, 26 and 
52 weeks in patients aged ≥65 years with VB12 deficiency 
treated at primary healthcare centres (PHC). Secondary 
outcomes included safety (adverse events), quality of life 
and adherence to treatment. Additional aims were to 
describe patient preferences and satisfaction with treat-
ment and to explore the immediate response (8 weeks) as 
a normalisation predictor of 1 year outcomes to propose 
clinical recommendations.
MethODs
study design and participants
A pragmatic, randomised, multicentre, non- inferiority 
clinical trial with a duration of 12 months was conducted 
in a PHC. On ethical grounds, a placebo- controlled trial 
was not appropriate.26 Methodological issues of this trial 
have been published elsewhere (online supplementary 
1).27
Competitive recruitment was performed in 22 PHC in 
Madrid (Spain) from July 2014 to November 2016. Eligible 
patients were 65 years of age or older and had been 
attending a PHC for consultation on any medical matter. 
Patients were assessed for eligibility and invited to partici-
pate consecutively by their general practitioners. Written 
informed consent was obtained from all participants. A 
blood test was performed, and in patients with a serum 
concentration of VB12 of <211 pg/mL, the remaining 
inclusion and exclusion criteria were evaluated. The cut- 
off value selected in the trial register/trial protocol was 
<179 pg/mL; this value was modified by the laboratory 
following the recommendations of the provider. This 
change took place prior to the beginning of the recruit-
ment. Patient recruitment was always performed using 
the same methodology and cut- off point. The procedures 
for measurement of the biomarkers were ADVIA Centaur 
XP (Siemens Diagnostics, Tarrytown, NY, USA).
randomisation and masking
Patients were allocated by simple randomisation at a 1:1 
ratio to oral or IM administration of VB12. The rando-
misation system was incorporated into the electronic 
data collection system to assure allocation concealment. 
Because of the nature of the intervention, patients and 
general practitioners were aware of their treatment allo-
cation. Analysis was performed by the trial statistician, 
who was blinded to allocation.
Intervention
The pharmaceutical formulations used in the study are 
commercially available in Spain (Optovite vials). Its phar-
maceutical presentation is in silk- screen- printed clear 
glass ampoules that are presented in blister support. The 
treatment regimen was : (a) IM route: 1 mg of cyanoco-
balamin on alternate days during weeks 1–2, 1 mg/week 
during weeks 3–8 and 1 mg/month during weeks 9–52; 
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(b) oral route: 1 mg/day of cyanocobalamin for 8 weeks 
and 1 mg/week during weeks 9–52. The period between 1 
and 8 weeks was considered the charging period.
In the oral route, the medication was provided to the 
patient at the health centre, along with instructions for 
self- administration at home. The information sheet 
explained to the patient the procedure for oral admin-
istration, that is, how to open the ampoule and dilute its 
contents in a glass, then drink it.
In the IM route, the medication was administered by 
the nurse at the health centre.
Outcomes
The main outcome was the normalisation of serum VB12 
concentrations (≥211 pg/mL) at 8, 26 and 52 weeks. The 
secondary outcomes were the serum VB12 concentra-
tions (pg/mL), adverse events, adherence to treatment 
(number of vials for the oral arm and the number of 
injections for the IM arm during each visit; good adher-
ence was considered greater than 80%), quality of life 
(EQ- 5D- 5L)28 and patient preferences and satisfaction 
were assessed. Anamnesis, demographic and lifestyle 
information, clinical variables, analytical variables and 
concomitant treatment were recorded.27
Procedures
After signing the consent form, those who agreed to partic-
ipate had serum VB12 concentrations determined. If the 
VB12 value was <211 pg/mL, a haemogram, biochem-
ical analysis and anti- intrinsic factor antibody levels 
were assessed.27 The patients also received a medication 
diary to be filled out daily. Baseline data were collected 
by the family physician and/or a nurse. IM treatments 
were administered by nurses in the health centres. The 
follow- up visits were conducted during weeks 8, 26 and 
52.27
statistical analysis
Sample size
Assuming that 70% of patients reach a serum VB12 
concentration of ≥211 pg/mL in both groups, for a 
threshold of non- inferiority of 10%, statistical power 
of 60% with significance set at p<0.05 and a 5% loss to 
follow- up, the final sample size was word 320 (160 in each 
arm).
As recommended for non- inferiority studies, both per- 
protocol (PPT) and intention- to- treat (ITT) analyses were 
performed, with the null hypothesis being that there were 
differences between treatments at the three monitoring 
points. Comparing both arms, we calculated the differ-
ence between the percentage of patients in each treat-
ment arm whose serum VB12 concentrations became 
normalised at 8, 26 and 52 weeks, with their 95% CI. If 
the CIs do not fall outside the non- inferiority limit (10%), 
it can be concluded that the oral treatment is not inferior 
to the IM treatment.29 30 In ITT analyses, missing values 
for the main outcome variable were added using the ‘last 
observation carried forward’ method.31
To explore factors affecting the normalisation of serum 
VB12 concentration at 52 weeks, serum VB12 levels were 
studied at 8 weeks. A receiver operating characteristic 
curve was built to determine the likelihood ratios of 
each cutpoint after the charging period to ‘predict’ the 
normalisation of levels at the end of the study. After this, 
a generalised linear model was built (function logit).32 33 
The normalisation of serum VB12 levels at 52 weeks was 
the dependent variable, and the treatment group was 
the independent variable. Variables considered signif-
icant by the researchers from a clinical perspective 
were included in the model. To test the non- inferiority 
hypothesis, adding the information contained in these 
data to previous knowledge, additional statistical analyses 
were performed using a Bayesian approach. Secondary 
outcome variables were analysed using the appropriate 
statistical tests, and their means or proportions were used 
to estimate differences between groups. All analyses were 
performed using STATA V.14 and EPIDAT V.4.2 software.
Patient involvement
Patients were not involved in the development of plans 
for recruitment, design, outcome measures or imple-
mentation of the study conduct. No patients were asked 
to advise on the interpretation or writing of the results. 
Patients explained the experience of participating in the 
study on the occasion of International Clinical Trial’s day 
in Radio Nacional de España. We will pursue patient and 
public involvement in the development of an appropriate 
method for further dissemination.
results
Characteristics of the study participants
A total of 2342 patients were offered participation, and 
2152 provided informed consent. A total of 307 patients 
showed a VB12 deficit (14.3%), 283 of whom were allo-
cated to receive VB12 treatment via the IM route (n=143) 
or orally (n=140). The follow- up period (52 weeks) was 
completed by 229 patients (80.9%). Losses to follow- up 
were similar in both regimens, 28 out of 140 and 26 out of 
143 losses in the oral and IM arms, respectively (p=0.697) 
(figure 1).
The average age was 75.2 (6.34), and 58.3% of the 
patients were women. Table 1 describes the baseline char-
acteristics of the patients included in the trial. No rele-
vant differences were found between groups at baseline 
for demographic and medical characteristics or for the 
study endpoints.
Primary outcomes
At week 8, the difference in the success rate between the 
oral and IM routes was −0.7% (95% CI: −3.2% to 1.8%; 
p=0.0999) and 4.8% (95% CI: −1.3% to 10.9%; p=0.124) 
with the PPT and ITT analyses, respectively. At week 26, 
these differences were −12.9% (95% CI: −17.9% to −6.1%; 
p<0.001) and −3.2% (95% CI: −11.8% to 5.4%; p=0.470), 
respectively. At week 52, these differences were −6.3% 
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2342 assessed for eligibility
190 declined to participate
• 44 lack of time
• 40 mistrust
• 35 declined to sign
• 33 fear
• 21 not  interested
• 17 others
171 declined to undergo blood test
1674 patients without B12 deficiency
2152 signed informed consent
307 VB12 deficiency
283 randomized
143 allocated to IM route:
• 135 received IM route
• 6 lost to follow-up
• 1 withdrawn for disease
• 1 other
140 allocated to oral route:
• 139 received oral route
• 1 lost to follow-up
274 
1st visit: start treatment 
265 
2nd visit: week 8
254 
3rd Visit: week 26
229 
4th visit: week 52
1 withdrawn for adverse events
4 lost to follow-up 
3 withdrawn for disease
1 lost to follow-up
1 withdrawn for not recovering levels
1 withdrawn for disease
6 lost to follow-up
3 withdrawn for disease
2 lost to follow-up
1 withdrawn for disease
17 withdrawn for not recovering levels
2 lost to follow-up
117 analysed per protocol
• 26 excluded from analysis
143 analysed by intention-to-treat
112 analysed per protocol
• 28 excluded from analysis
140 analysed by intention-to-treat
2 withdrawn for not recovering levels
1 lost to follow-up
24 excluded:
• 7 receiving anticoagulation treatment
• 4 receiving vitamin VB12
• 3 dropout
• 2 folic ac. concentration < 2.3 ng/ml
• 1 severe disease
• 7 others
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Figure 1 Trial profile.
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Table 1 Baseline characteristics at baseline by group
Variable
No (%)
Oral route (n=140) IM route (n=143) Total (n=283)
Sociodemographic data
  Women 87 (62.1) 78 (54.5) 165 (58.3)
  Age (years), mean (SD) 74.2 (5.8) 76.2 (6.7) 75.2 (6.3)
  Educational level
  Illiteracy 4 (2.9) 7 (5.1) 11 (4.0)
  Incomplete education 48 (34.5) 46 (33.6) 94 (34.1)
  Primary education 58 (41.7) 63 (46.0) 121 (43.8)
  Secondary education 16 (11.5) 10 (7.3) 26 (9.4)
  Tertiary education 4 (2.9) 4 (2.9) 8 (2.9)
  Higher education 9 (6.5) 7 (5.1) 16 (5.8)
  Social occupational class*
  Classes I–IV 31 (27.7) 33 (27.3) 64 (27.5)
  Classes V–VI 81 (72.3) 88 (72.7) 169 (72.5)
  Living alone 32 (21.4) 30 (22.2) 62 (21.9)
Clinical data
  Tobacco habit
  Ex- smoker 27 (19.7) 25 (18.4) 52 (19.0)
  Smoker 9 (6.6) 10 (7.4) 19 (7.0)
  Non- smoker 101 (73.7) 101 (74.3) 202 (74.0)
  Vegetarian 2 (1.4) 0 (0) 2 (0.7)
  Having undergone gastrectomy 1 (0.7) 2 (1.4) 3 (1.1)
Symptoms
  Paresthesia 33 (23.6) 45 (31.5) 78 (27.6)
  Asthenia 43 (30.7) 54 (37.8) 97 (34.3)
  Loss of appetite 12 (8.6) 30 (21.0) 42 (14.8)
  Sadness 37 (26.4) 53 (37.1) 90 (31.8)
  Showing ≥1 symptom 70 (50.0) 83 (58.0) 153 (54.1)
Signs
  Glossitis 2 (1.4) 9 (6.3) 11 (3.9)
  Position sensitivity 2 (1.4) 1 (0.7) 3 (1.1)
  Vibration sensitivity 15 (10.7) 13 (9.1) 28 (9.9)
  Showing ≥1 altered sign 16 (11.4) 21 (14.7) 37 (13.1)
Haemogram- clinical biochemistry
  Vitamin B12 (pg/mL), mean (SD) 173.1 (27.3) 166.4 (32.6) 169.7 (30.2)
  Anaemia† 16 (11.4) 27 (18.9) 43 (15.2)
  Haematocrit (%), mean (SD) 42.4 (4.0) 41.9 (4.2) 42.1 (4.1)
  MCV (fL), mean (SD) 92.1 (6.7) 94.3 (7.4) 93.2 (7.1)
  Anti- intrinsic factor antibody 15 (11.0) 15 (10.5) 30 (10.8)
Medication
  Proton- pump inhibitors (PPI) 57 (40.7) 64 (44.8) 121 (42.8)
  Metformin 69 (49.3) 56 (39.2) 125 (44.2)
  PPI and metformin 33 (23.6) 30 (21.0) 63 (22.3)
Scales
  MMSE‡, mean (SD) 30.8 (4.6) 30.2 (4.8) 30.5 (4.7)
Continued
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Variable
No (%)
Oral route (n=140) IM route (n=143) Total (n=283)
  EQ- 5D- utilities, mean (SD) 0.817 (0.169) 0.855 (0.139) 0.836 (0.171)
*Neoweberian occupational social class (CSO- SEE12).41
†Anaemia was defined by the WHO criteria (haemoglobin <12 g/L in women and <13 g/L in men). https://www.who.int/vmnis/indicators/
haemoglobin.
‡Maximum score=35 points. Normal score=30–35. Borderline score=24–29 points. Scores <24 points in patients aged >65 years and scores 
<29 points in patients aged <65 years suggest cognitive impairment.
IM, intramuscular; MCV, Mean Corpuscular Volume; MMSE, Mini Mental State Examination.
Table 1 Continued
Figure 2 Difference between the oral and intramuscular routes in the proportion of patients whose VB12 levels returned to 
normal (≥211 pg/mL). IM, intramuscular; ITT, intention- to- treat; PPT, per- protocol.
(95% CI: −11.9% to −0.07%; p=0.025) and −6.8% (95% 
CI: −16.6% to 2.9%; p=0.171), respectively (figure 2).
In the PPT analysis under a Bayesian approach, the 
probabilities of differences in the treatment effectiveness 
being >10% between the oral and IM groups were 0.001, 
0.201 and 0.036 at weeks 8, 26 and 52, respectively. In the 
ITT analysis, these values were 0.000, 0.015 and 0.060 at 
weeks 8, 26 and 52, respectively (online supplementary 
2). The result of the likelihood ratio for the cutpoints at 
the main percentiles of the distribution of VB12 serum 
levels at week 8 to predict normalisation at the end of 
the study is shown in online supplementary 3. The level 
at the fifth percentile of the distribution was selected as 
the most useful value because it showed the best classifi-
cation ability. When patients did not reach this level at 
week 8, they were almost 12 times more likely to not reach 
suitable VB12 levels at the end of the study than if they 
had reached levels over 281 pg/mL (12~1/negative like-
lihood ratio).
In the ITT analysis, the factors affecting the success rate 
at week 52 were age, for each year of increase in age, the 
success rate decreased by 5%, and having attained VB12 
levels of ≥281 pg/mL at week 8, which yielded a success 
rate 8.1 times higher (table 2).
The mean levels of VB12 for each follow- up visit were 
above the normalisation threshold in both groups, 
although these values were much greater in the IM group 
(online supplementary 4). In 51 patients (46 IM and 5 
oral), the levels of VB12 in week 8 were above the normal 
range limit of the laboratory (≥911 pg/mL), so the treat-
ment regimen was changed from the initial planned 
pattern.
secondary outcomes
In terms of quality of life and the presence of signs related 
to VB12 deficiency, no significant differences were found 
between treatment arms at any of the follow- up visits 
(table 3).
Eleven adverse events were reported and none of 
them were severe; five (3.57%) occurred with patients 
in the oral arm and six (4.20%) with patients in the IM 
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Table 2 Factors associated with VB12 concentrations ≥211 pg/mL at week 52
Variable OR Robust SE P>z 95% CI
IM vs oral route 1.10 0.370 0.776 0.57 to 2.13
Age 0.95 0.022 0.025 0.91 to 0.99
VB12 concentration >281 pg/mL at week 8 8.10 5.014 0.001 2.41 to 27.25
Constant 0.78 0.622 0.755 0.16 to 3.72
GLM, N=265. Variance function: V(u) = u*(1−u/1) [Binomial]. Link function: g(u) = ln(u/(1−u)) [Logit]. Akaike Information Criterion= 0.89967. 
Bayesian Information Criterion= −1225.89.
Table 3 Secondary outcomes (quality of life and exploratory findings) at weeks 8, 26 and 52
Visit
Oral route IM route
P value Mean difference (95% CI)N Mean (SD) N Mean (SD)
Quality of life (EQ- 5D- 5L Index)
  Baseline 139 0.855 (0.139) 137 0.817 (0.197) 0.066 0.038 (−0.002 to 0.078)
  Week 8 134 0.853 (0.158) 130 0.822 (0.204) 0.173 0.031 (−0.013 to 0.075)
  Week 26 128 0.853 (0.153) 122 0.826 (0.191) 0.219 0.027 (−0.016 to 0.070)
  Week 52 112 0.824 (0.179) 117 0.823 (0.194) 0.958 0.001 (−0.047 to 0.049)
GLM, generalised linear model; IM, intramuscular.
At least one altered sign (glossitis and/or altered vibration sensitivity and/or altered position sensitivity)
Visit N n (%) N n (%) P value Proportion difference (95% CI)
Baseline 140 16 (11.4) 143 21 (14.7) 0.416 −3.3 (−11.1 to 4.6)
Week 8 135 15 (11.1) 130 13 (10.0) 0.769 1.1 (−6.3 to 8.5)
Week 26 131 14 (10.7) 122 12 (9.8) 0.824 0.9 (−6.6 to 8.3)
Week 52 122 14 (12.5) 117 9 (7.7) 0.226 3.8 (−3.7 to 11.2)
arm, yielding a difference of −0.63% (95% CI: −5.12% 
to 3.87%, p=0.786). Three patients withdrew from the 
study: one patient in the oral group due to urticaria, and 
two in the IM group due to reddening and pruritic facial 
erythema and generalised itching (mainly in the cheeks 
with scarce urticariform lesions). In three other cases, 
treatment for the adverse events was prescribed (consti-
pation and erythema), and in five cases, it was not neces-
sary to take further measures (table 4).
At week 8, adherence to treatment was evaluated in 265 
patients, of whom 95.5% were adherent (97.8% oral and 
93.8% IM); the difference between the groups was 4% 
(95% CI: −0. 1% to 8.7%; p=0.109). At week 52, adher-
ence was evaluated in 229 patients, of whom 220 (96.1%) 
were adherent (98.2% oral and 94.0% IM); the difference 
was 4.2% (95%CI: −0.7% to 9.1%; p=0.172).
Overall, 89.5% of the patients reported being satisfied 
or very satisfied with the treatment via the oral route 
(91.3%) and the IM route (87.6%). The difference was 
3.7% (95% CI: −4.0% to 11.3%; p=0.348).
A total of 83.4% of patients preferred the oral route 
(97.6% among the patients receiving VB12 orally vs 
68.6% of the patients in the IM group); the difference was 
29.0% (95% CI: 20.3 to 37.7; p<0.001). The preferences 
expressed by the patients referred to their potential 
choice regardless of the arm to which they were assigned.
DIsCussIOn
Main findings of the study
Supplementing VB12 in patients with VB12 deficiency, 
whether orally or intramuscularly, achieves the normal-
isation of VB12 levels in most cases. The oral route was 
not inferior to the IM route during the charging period. 
Formally, the pre- established conditions for determining 
the non- inferiority of oral administration were not met 
for the complete follow- up period, but these results merit 
a deeper analysis.
Differences between the administration routes were 
found at 26 and 52 weeks. The IM maintenance treat-
ment of 1 mg/month was effective in maintaining VB12 
levels, while oral administration of 1 mg/week had a 
probability of being inferior (by more than 10%) to 
the IM route by 20% in the most unfavourable scenario 
(PPT). However, given that no strategy was superior in the 
charging period, and in view of the model results showing 
that when VB12 levels reached ≥281 pg/mL during the 
charging period, the success rate at 12 months was eight 
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Table 4 Description of adverse events by patient and route 
of administration
Route Adverse event Action
IM route Constipation Administration of 
specific treatment
Generalised itching and 
hives on the cheeks
Withdrawal
Dyspepsia Treatment not 
required
Constipation Administration of 
specific treatment
Redness and pruritic facial 
erythema
Withdrawal
Erythema on forearms Administration of 
specific treatment
Oral 
route
Urticaria on the neck and 
arms
Treatment not 
required
Occasional postprandial 
dyspepsia
Treatment not 
required
Occasional postprandial 
dyspepsia
Treatment not 
required
Urticaria Withdrawal
Increased irritability and 
nervousness
Treatment not 
required
IM, intramuscular.
times higher, the probability that the differences between 
groups would exceed Δ was very low, independent of the 
administration route. The most plausible explanation for 
the observed difference between routes might be that in 
patients below this threshold, the maintenance oral dose 
should be higher than the dose used in the present study. 
Some authors have recommended that an oral dose of 2 
mg/week be administered as a maintenance dose.34
The incidence of adverse events was very low and 
similar for oral and IM administration, and non- serious 
adverse events were found. These findings were similar 
to other studies.5 Patients’ preferences can be a decisive 
factor for determining the administration route. In this 
trial, similar to previous studies,17 there was a clear pref-
erence for the oral route, especially among the patients 
assigned to this group.
The effect of VB12 supplements on quality of life 
remains unclear,35 36 but the present results show that the 
treatment route does not improve patients’ perception of 
their health- related quality of life or related symptoms.
We did not find significant differences in adherence. 
Adherence to the treatment via the IM route was lower 
than expected. Although drug administration was assured 
once the patient attended the consultation, the patient 
could choose not to attend appointments for various 
reasons. However, in usual practice, adherence with the 
oral route could be more compromised than with the IM 
route, and this factor should be taken into consideration 
to personalise prescription.
Comparison with other studies
The comparison with other studies is difficult, due to the 
treatment different doses used, but especially because of 
the follow- up length had been inferior to 4 months and 
the number of patients included was small.
As far as we know, the present trial is the largest clinical 
trial with the longest follow- up period, and it is the first 
to evaluate, in addition to VB12 levels, clinical signs and 
symptoms, health- related quality of life and patient pref-
erences. The three clinical trials23–25 described in the 2018 
Cochrane Systematic Review5 had a duration between 3 
and 4 months and included a total of 153 patients. In the 
Saraswathy trial, patients in the oral route at 3 months 
normalised levels 20/30 (66.7%) versus 27/30 (90%) 
of the patients in the IM route.25 In Kuzminski’s trial, 
patients in the oral route at 4 months normalised levels 
18/18 (100%) versus 10/14 (71.4%) of the patients in 
the IM route.23 These differences were statistically non- 
significant in both studies.
Two studies have recently been published and add 
evidence in favour of oral and sublingual administration 
of VB12.37 38 The follow- up of Moleiro’s study reached 24 
months versus 12 months in our study. However, Moleiro 
et al performed a prospective uncontrolled study that 
included 26 patients submitted to total gastrectomy. All 
patients received oral VB12 supplementation (1 mg/
day), and all of them maintained normalisation V12 at 6, 
12, 18 and 24 months. There was a progressive increase 
in serum V12 levels within the first 12 months, which 
remained stable thereafter.37 The long- term effectiveness 
of the oral route in absorption- deficient people such as 
gastrectomised patients would support the results of our 
study.
Bensky et al compared the efficacy of sublingual versus 
IM administration of VB12 in a retrospective observa-
tional study from the computerised pharmacy records 
of Maccabi Health Service. Among 4281 patients treated 
with VB12 supplements (830 (19.3%) with IM and 3451 
(80.7%) with sublingual tablets), the IM group achieved 
a significant increase in VB12 levels compared with the 
sublingual group, OR 1.85, CI 95% 1.5 to 2.3.38 Although 
this study has a large sample size, the important meth-
odological limitations on its effectiveness (retrospective 
design; reliance on clinical records; absence of epidemi-
ological information such as patient age and sex or the 
aetiology of the deficit) should be considered in the inter-
pretation of their results.
strengths and limitations
Our study was pragmatic39 in both the inclusion and 
diagnostic methods criteria. The majority of the patients 
with deficits included in this study presented no symp-
tomatology or very low- level symptoms, with no anaemia, 
which is the common profile of most patients who present 
with VB12 deficits in primary care. The study design did 
not allow for masking the patients to the received treat-
ment. However, these limitations were compensated 
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for by the objective measurement of the main outcome 
variable.
As occurs in all pragmatic clinical trials, patient recruit-
ment was complicated, and the sample size reached only 
88.4% of the calculated necessary size, which implies that 
the power of the study was limited. Hence, the analysis 
was complemented using Bayesian methods that allow 
for studying a posteriori the likelihood of a difference 
between two outcomes to exceed a certain limit.40 Under 
this approach, the a posteriori probability for differences 
to exceed the proposed Δ=−10% was not significant 
during the charging period, and the probabilities were 
low but not negligible in the PPT analysis and low in the 
ITT analysis over the complete follow- up period.
Loss to follow- up was low at 8 and 26 weeks and higher 
at 52 weeks. This effect has been observed in pragmatic 
clinical trials with long follow- up periods. Missing data 
were greater in the IM arm, during the interval between 
randomisation and initiation of treatment (6% IM vs 1% 
oral), over 8 weeks (9% IM vs 4% oral) and over 26 weeks 
(15% IM vs 6% oral). These differences could represent 
a lower acceptability of the IM route by patients, since the 
missing data were mostly due to patient dropout. At 52 
weeks, the numbers of losses in the two arms were similar 
(20% oral and 18% IM), and in the case of oral treat-
ment, several of those losses were withdrawals occasioned 
by not achieving particular levels of VB12.
Implications of the study findings
On the basis of our results and the available evidence, 
we propose the oral administration of VB12 at 1 mg/day 
during the charging period. Subsequently, the recom-
mended dose would vary as a function of the VB12 levels 
reached during the charging period. For VB12 concen-
trations between the normal levels of 211 pg/mL (in our 
laboratory) and 281 pg/mL (the fifth percentile of the 
distribution in this trial), a dose of 2 mg/week is suggested. 
When the levels reached in the charging period are 
between 281 and 380 pg/mL (the 20th percentile of the 
distribution), it may be appropriate to perform an anal-
ysis between 8 and 26 weeks to confirm that normal levels 
are maintained. All patients who reach a level of 380 pg/
mL by week 8 could be maintained at the initial dosage (1 
mg/week) without subsequent analyses during the year 
of follow- up.
If the IM route is chosen, the proposed dose for this 
route during the first few weeks may be excessive for 
patients with VB12 deficiency. The scheduled IM dose 
should be reconsidered in the first 2 weeks based on VB12 
levels, and the scheduled dose could be limited to 1 mg/
week if warranted by the outcome. Nevertheless, these 
recommendations must be assessed in further research.
Oral administration of VB12 in patients older than 65 
years is probably as effective as IM administration, and 
it also lacks adverse effects and is preferred by patients. 
We must also highlight the potential benefit of the oral 
route in terms of safety for patients with coagulation 
problems, for whom IM- administered medication is often 
contraindicated. A small number of patients may require 
additional follow- up after 8 weeks if a certain concentra-
tion of VB12 in blood is not reached.
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